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Abstract
Background: The treatment outcome of advanced stage uterine cervical carcinoma remains unsatisfactory. In order to elaborate a novel
trial within The Radiotherapy Cooperative Group (RCG) of the European Organization for Research and Treatment of Cancer (EORTC), we
conducted a survey in 1997±1998 to determine the variability of pre-treatment assessment and treatment options. The variability of choosing
surgery, de®ned radiation therapy techniques and chemotherapy are investigated, as well as the center's choices of future treatment strategies.
Methods: Fifty two of 81 RCG centers from the RCG have participated in the survey. As one would expect, there is a large variation in the
techniques used for pretreatment evaluation and treatment options. There is no `standard' for reporting acute and late side effects.
Chemotherapy is used neither systematically nor uniformly, and some centers continue to use neadjuvant chemotherapy modalities.
Results: Furthermore, the survey reveals that there is a strong demand for the reduction of overall treatment-time, for clinical investigation
of novel combined modality treatment strategies, especially chemo±radiation therapy, and also for the use of new radiation sensitizers.
Conclusion: We conclude that a more homogeneous approach to the pretreatment evaluation as well as treatment techniques is required in
order to allow adequate quality control in any future trial of the RCG in the EORTC. q 2000 Elsevier Science Ireland Ltd. All rights reserved.
Keywords: Cervix cancer; Pretreatment evaluation; Surgery; Chemo±radiotherapy
1. Introduction
The Radiotherapy Cooperative Group (RCG) of the
European Organization for Research and Treatment of
Cancer (EORTC) is conducting a variety of trials for differ-
ent tumor localizations. However, gynecological tumors are
currently not the subject of any ongoing trial, notwithstand-
ing the fact that radiation therapy plays a major role in the
treatment of cervical carcinoma. There is one ongoing inter-
group trial (EORTC-GCCG) investigating the usefulness of
the addition of cisplatin-based chemotherapy to postopera-
tive radiation therapy in stages Ib and IIa cervical carcinoma
after radical hysterectomy and complete lymphadenectomy.
There is not a single trial addressing the question of
adequate treatment for locally-advanced cervical cancer
(LACC), i.e. FIGO stages IIb, IIIa and IIIb. This is dif®cult
to understand, facing the multitude of open questions related
to the optimal investigational approach and therapeutic
management of cervical carcinoma.
In order to de®ne whether there is an interest within the
RCG to study new therapeutic concepts in LACC, we sent
a questionnaire to radiotherapy groups which are listed as
participating members of the RCG. This questionnaire is
designed to determine the general feasibility of a trial in
Europe, taking into consideration the decreasing number of
patients with LACC addressed to radiation therapy depart-
ments. Finally, we try to de®ne which questions have to be
given priority in future trials. Special attention is dedicated
to the concept of the association of chemotherapy and
ionizing irradiation, the concept of the impact of treatment
duration on local control, and to the use of `new' radio-
sensitizers. The answers on this questionnaire are analyzed
and discussed, taking into account the `guidelines' and/or
`evidence' reported in currently published literature.
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The questionnaire was designed in 1997 and sent to 81
RCG centers. The questionnaire contains general questions
related to the number of patients (on a yearly basis) treated
in the individual RCG centers, their stage distribution, the
techniques used in the pretreatment evaluation and the ther-
apeutic options considered as `standard'. For the latter,
speci®c questions address the relative role and sequence
of the four basic therapeutic options, namely surgery,
chemotherapy, external irradiation and brachytherapy.
Regarding external irradiation, special attention is given to
technical details related to the treated volumes, number of
®elds used, total dose and dose/fraction, and prescription
point. The importance of brachytherapy is reported again
with some details on dose-rate, number of applications, in
vivo dosimetry and timing with external treatment. The
questionnaire aims to de®ne the relative importance of
chemotherapy, the type of chemotherapy, i.e. neoadjuvant,
concomitant or sequential, and the most frequent drugs
used. One question concerns the toxicity scale used to report
the acute and late side effects.
Finally, bearing in mind the more general question raised
by the RCG, i.e. the feasibility of a trial within the EORTC,
the centers are asked if they will participate in a general
effort to run such a trial. The RCG members are asked to
state if they are interested in investigating the importance of
the package-deal concept (the time factor), the importance
of chemotherapy or the use of `new' sensitizers.
3. Results
Fifty two centers out of 81 (64%) answered the question-
naire. The average number of patients/year addressed to the
departments of radiation±oncology is 48 (median value 24,
range 5±600). These patient numbers are listed in Table 1
according to stage distribution. Considering LACC (de®ned
as IIb±IIIa±IIIb), we recorded a mean value of 25 (median
15, range 1±358) new patients/center per year.
3.1. Pretreatment evaluation and staging
One of the ®rst important questions is related to T and N
staging. For the clinical evaluation of local tumor in®ltra-
tion, routine cystoscopy is rated high (89%) alongside the
digital gynecological examination, but only 56% of the
centers mention routine rectoscopy. The use of transvaginal
ultrasound has not been recorded in this questionnaire.
Ninety four percent of the centers reported practicing
nodal staging. Evaluation of nodal involvement is mainly
performed with computed tomography (CT) (85%) and
nuclear magnetic resonance (NMR) (50%). Patients are
less frequently submitted to surgical staging (35%). The
technique used for surgical staging is laparatomy (23%),
or coelioscopy (21%). Unfortunately, no data are available
in order to determine how much of these surgical stagings
are associated with a radical hysterectomy, and the rate of
surgical staging in respect of stage.
Lymphangiography (LAG) as part of the routine pretreat-
ment work-up has been reported by only seven centers
(14%).
3.2. Treatment options and treatment sequence
3.2.1. Surgery
The possible treatment policies include surgery, external
irradiation, brachytherapy and chemotherapy. As illustrated
in Fig. 1a, the use of curative surgery as the initial approach
to treatment decreases as the FIGO stage increases. The
importance of radiotherapy (Fig. 1b) and brachytherapy as
primary treatments (Fig. 1c) progressively increases with
higher FIGO stages. Sixteen centers use surgery as part of
the treatment for stage IIb, six for stage IIIa, ®ve for stage
IIIb, and ten centers for stage IVa. Moreover, four centers
record surgery as upfront treatment in IIb, one in IIIa and
four in IVa. Surgery is the preferred ®rst-line treatment
modality in stage Ia (83%), Ib (73%) and IIa (60%). Surgery
includes at least hysterectomy with or without node
sampling or node dissection. More details on the surgical
procedure are not available.
3.2.2. External beam irradiation
External irradiation is more likely to be used as a ®rst-line
treatment for IIb and higher stage disease. The use of radia-
tion as a ®rst-line treatment modality or as part of a
combined treatment-approach in respect of stage is summar-
ized in Table 2.
Thirty out of 52 centers (58%) are using 2D planni®ca-
tion, i.e. using one single CT-slice at the center of the ®elds,
whereas 23 (44%) are using 3D (a series of CT-slices). Six
out of 52 centers (12%) use neither 2D nor 3D for dose-
calculation for external beam radiation therapy. Five out of
these six centers are located in western Europe. Five centers
use 2D or 3D according to the complexity of the case. The
median dose for external irradiation is 45 Gy, but with a
range of 36±70 Gy according to the center and tumor stage.
The median number of fractions/week is ®ve (range 5±10)
with a median dose/fraction of 2 Gy (range 1.5±2 Gy). This
external treatment is usually given by a four-®eld box tech-
nique on the pelvis (85%). However, in eight centers, an
AP±PA ®eld is still used to cover the pelvic volume. If
para-aortic nodes are considered as the target, these nodes
are covered by AP±PA ®elds by the majority of the centers
(67%). The median number of ®elds treated daily for the
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Table 1
Distribution of number of patients/stage per year
Stage IA IB IIA IIB IIIA IIIB IVA IVB
Meana 7 14 6 9 4 12 3 3
Mediana 3 6 4 6 3 6 2 3
a Number of patients/center per year.
pelvic volume is four, and two for the para-aortic volume.
The para-aortic nodes are never treated by ®ve centers
(10%). Forty-six centers (89%) are covering those nodes
if they are found to be positive during pretreatment evalua-
tion, whatever the technique used (CT, NMR or surgical
staging), and 22 centers (42%) are including those nodes
within the target volume if the pelvic nodes are positive.
3.2.3. Brachytherapy
Brachytherapy is used to boost external radiation espe-
cially in stages IIb, IIIa and IIIb (58, 71 and 77%, respec-
tively). In Table 3, we have summarized the percentage of
centers using brachytherapy as part of the treatment accord-
ing to FIGO stage. The dose speci®cation for the
brachytherapy is `Point A' in 29 centers (56%), an isodose
envelope in 18 centers (35%), and three centers (6%) do not
really specify their reference point. Brachytherapy is essen-
tially applied after the completion of the external irradiation
(35 centers, 67%), but in 16 centers (31%) it is given during
irradiation, and for seven of these centers there is at least
one brachytherapy application after the end of the external
irradiation. The centers have reported a range of fractions
for the brachytherapy of 1±8, with a median value of two for
LDR and three for HDR. The median cumulative dose at the
reference point is tailored according to stage and to the
external radiotherapy dose. Brachytherapy is subdivided
according to the dose-rate, resulting in high dose-rate
(HDR, .l2 Gy/h), medium dose-rate (MDR, 2±12 Gy/h)
and low dose-rate (LDR, ,2 Gy/h). A majority of centers
(64%) are using LDR, 31% use HDR, 4% use MDR and one
center uses both LDR and HDR. The ranges and median
values at the reference point for the individual stages Ia,
Ib, IIa, IIb, IIIa, IIIB, IVa and IVb are listed in Table 4
according to the dose-rate. The progressive reduction in
dose applied by brachytherapy for increasing stages re¯ects
the growing importance of the external irradiation compo-
nent. In vivo dosimetry at the level of the bladder and the
rectum is rarely performed, 13 and 31% of the centers
reporting it, respectively.
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Table 2
Use of external irradiation as ®rst-line (A), or as a component of treatment
(B), according to FIGO stagea
RTH Ia Ib IIa IIb IIIa IIIb IVa IVb
A ± ± ± 71 87 92 67 39
B 15 54 54 89 96 98 83 58
a Number of centers reported in % of total number.
Table 3
Use of brachytherapy as ®rst-line or as a component of `curative' treatment
according to FIGO stagea
Ia Ib IIa IIb IIIa IIIb IVa IVb
27 69 71 90 88 92 44 27
a Number of centers reported in % of total number.
Fig. 1. Treatment sequence according to FIGO stage. The centers were
asked to report the curative treatment modalities in function of priority.
Places of (a), surgery; (b), external radiation therapy; (c), brachytherapy;
and (d) chemotherapy in the treatment sequence.
3.2.4. Reporting radiation side effects
Radiation side effects are reported using different grading
scales; the more recently published LENT/SOMA has not
gained wide acceptance since six centers (12%) are using
this scale for acute side effects and nine centers (17%) for
late side effects. The French±Italian glossary [5] is more
frequently used (acute effects: 19 centers, i.e. 37%; late
effects: 24 centers, i.e. 46%). This is followed by the
World Health Organization (WHO: l7 acute and 13 late)
and the Radiation Therapy Oncology Group (RTOG: l4
acute and 13 late) grading systems. Fifteen centers use
more than one grading system to report side effects, i.e.
they mix up a scale for early effects from one group with
a scale for late effects from another group. Thirty ®ve
centers (67%) consistently use the grading system issued
from the same group (mainly the French±Italian glossary)
to report acute and late effects.
3.2.5. Chemotherapy
Chemotherapy is divided into neoadjuvant (prior to de®-
nitive local treatment, such as surgery or radiotherapy),
concomitant (synchronous combination with external irra-
diation) and sequential (alternating with external radiation
therapy). Neoadjuvant chemotherapy is used by 11 centers,
concomitant chemo±radiation therapy by 15 and sequential
by six. The indications for chemotherapy are FIGO stage-
dependent. None of the centers report any form of
chemotherapy in stage Ia compared to 23 centers, i.e.
44%, in the case of stage IVb. Neoadjuvant chemotherapy
is more frequently applied in more advanced diseases. For
example, seven centers report neoadjuvant chemotherapy
for stage IIb, nine for stage IIIa and eleven for stage IIIb.
There is a general trend to introduce more and more
chemotherapy with higher stage disease. Cisplatin is the
most commonly used chemotherapeutic agent.
3.3. New approaches
One of the primary aims of the present questionnaire is to
determine the interest in the RCG within the EORTC in
conducting a phase III trial. Forty one out of 52 centers
(79%) are willing to participate to a prospective trial.
Most of the latter are interested in a trial investigating the
importance of chemotherapy in LACC, especially in the
setting of concomitant use of chemotherapy (33 centers 
64%). It should be noted that the questionnaire was
addressed to the centers before the data on the effect of
cisplatin in LACC was available.
The question relating to the importance of total treatment
duration (reducing the package-deal concept) was found to
be a worthwhile test in a randomized trial in 25 centers
(48%). The concept of innovative approaches and especially
the testing of `new' sensitizers in a phase I/II trial was
accepted by 29 centers (56%), with the majority (16/29)
choosing taxol. Other possible `new sensitizers' generating
interest in the questionnaire were gemcitabine (11 centers),
CPT-11 (eight centers), iodo-deoxy-uridine (®ve centers),
tirapazamine (four centers). Hydroxyurea was not reported
as an interesting agent to be tested.
4. Discussion
This survey, established initially to evaluate the feasibil-
ity of a trial within the EORTC-RCG in LACC, results in an
interesting amount of information concerning staging and
treatment habits in Europe. The ®rst relevant point is the rate
of response to the survey. Sixty four percent of the centers
have answered to the questions raised, and therefore this
survey yields a representative estimation of staging and
treatment habits in the RCG centers of the EORTC. The
most important information is the large variation in patient
care, and this, although expected, has not yet been docu-
mented.
4.1. Pretreatment evaluation and staging in cervical cancer
Tumor stage (T) is, with nodal stage (N), one of the most
important prognostic factors. To assess T and N stage, an
extensive local and regional examination is necessary. T can
easily be assessed by digital rectal and vaginal examination
under anesthesia. The clinician should not only report tumor
stage, but also tumor size, because the latter behaves as an
independent prognostic factor, as shown in a recently
published multivariate analysis [1]. However, tumor size
is rarely reported.
We initially expected a large majority of centers reporting
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Table 4
Range and median values in Gy of brachytherapy doses according to stage and dose-ratea
Ia Ib IIa IIb IIIa IIIb IVa IVb
MDRb ± 21 21 24 24 24 24 ±
HDR 10±28 10±30 10±35 10±35 9±40 9±40 10±40 10±40
Median 17 17 18 18 18 20 18 17
LDR 20±70 20±80 20±70 10±70 10±60 10±60 10±50 19±60
Median 60 40 45 40 35 35 30 20
a The ranges in total dose at the reference point are explained by variation of the relative importance of brachytherapy in the treatment protocol in the
different centers.
b MDR-data bases on reports from two centers.
both cystoscopy and rectoscopy as routine procedures for
clinical evaluation of local tumor extent. While cystoscopy
is rated in nearly all centers, only slightly more than half of
them are reporting rectoscopy as a routine procedure.
One of the most challenging problems in the diagnostic
procedure is to detect lymph-node disease, as its presence
changes the prognosis, and hence, treatment. The literature
reports a 20±40% discrepancy between surgical and clinical
staging [31], and some authors claim that there is a role for
debulking of pelvic node metastases, as this debulking may
result in increased cure-rates [9,31]. Most of the centers
report a procedure for the detection of lymph-node metas-
tases, but there is a large variation in the techniques used.
Surgical staging is performed in about one quarter of the
centers. If pelvic lymph-node staging is performed surgi-
cally, retroperitoneal staging should be preferred as it is
less morbid than transperitoneal staging [9,31]. Our ques-
tionnaire does not allow us to assess whether lombo-aortic
sampling is performed in centers which mention a surgical
procedure.
If non-surgical techniques are used for the assessment of
lymph-node stage, one has to mention that the lymphangio-
graphy (LAG) remains the best available technique,
although this procedure is rarely performed in the present
day. This is mainly due to the lack of expertise, and there-
fore the technique risks being discarded as part of the
routine diagnostic work-up. Only a minority of centers
(14%) in our study use LAG for nodal status evaluation,
most of them use CT or NMR, which are known to be
less sensitive and speci®c than LAG. However, as shown
by the Gynecologic Oncology Group (GOG), LAG has a
sensitivity of 79% and speci®city of 73%, whereas CT and
ultrasound have sensitivities of 34 and 19%, and speci®ci-
ties of 96 and 99%, respectively [15]. The importance and
utility of LAG, especially if external radiotherapy is
planned, is con®rmed by the work of Bonin et al., who
demonstrated that bony landmarks are not an adequate
substitute for LAG for the localization of pelvic lymph
nodes [3]. Some authors are convinced that LAG remains
the tool of choice in order to de®ne target volumes and ®eld
limits for external radiation [3].
In conclusion there is a clear shift in diagnostic work-up,
with a decrease of the importance of LAG to 14%. This can
be compared with the 11±18% reported in the patterns of
care study of Perez and Montana [25,27]. The reduction in
the use of LAG corresponds with an increase to 85% in the
use of CT (compared to 70% in the patterns of care study),
although a poor correlation between CT and surgical staging
has been documented (50±60%). In our study, 50% of the
centers are using MRI, although the accuracy of MRI in
detecting metastatic lymph nodes has not been established.
Surgical nodal staging is performed in 18 centers, and
hence, declining frequency in the use of LAG is not
compensated by a more frequent use of surgical staging.
The shift towards CT and/or MRI in the staging procedure,
and away from LAG, results in a potential loss of accuracy
of the diagnostic work-up. This has to be considered in
reviewing the therapeutic results and comparing these
with the historical series, in which LAG was considered
as standard.
4.2. Treatment options and treatment sequence
4.2.1. Surgery
Most of the centers are advocating curative surgery for
early stage cervical cancer. Our results are therefore similar
to a survey performed in the USA, highlighting a progres-
sive increase in the implication of gynecological oncologi-
cal surgeons in the primary treatment of early cervix cancer.
In our survey, radiation therapy seems to be less frequently
used for early stage disease, decreasing from 70 to 60.3%, as
either the only treatment or in combination with other treat-
ment modalities [34]. This trend in stage Ib±IIa cervical
cancer seems not to be evidence-based, taking into account
the randomized study reported by Landoni et al. [22]. That
trial compares curative surgery to curative radiation therapy
in early stage cervix cancer. The 5-year actuarial survival is
identical in both arms of the trial (83%), but there is a
signi®cant difference favoring external radiotherapy as far
as severe morbidity, especially urological, is concerned (28
vs. 19%). The combination of surgery and radiotherapy
yields the highest morbidity, especially regarding late-
responding normal tissues. Therefore, optimal selection is
required for surgery, leaving only premenopausal women
with normal ovarian function and with cervical diameters
of less than 4 cm as potential candidates for primary
surgery, assuming there is no suspicion of nodal involve-
ment [10,22]. Furthermore, emphasis should be put on total
cost in clinical practice, with a net increase if hysterectomy
and postoperative radiotherapy are compared to radiation
therapy alone in stage Ib±IIb [8].
It is noteworthy that a number of centers report surgical
options in LACC even as a ®rst-line curative treatment in
the present survey. To our knowledge, there is, however, no
evidence supported by any randomized trial suggesting that
such an aggressive surgical approach would yield any bene-
®t in patients who will need subsequent high-dose radiation
therapy.
4.2.2. Radiotherapy
Three different aspects of radiation therapy deserve
special attention: the de®nition of the target volume, the
volumes to be treated by external radiation and the
brachytherapy.
To obtain optimal treatment, one needs to adequately
de®ne the target volume. A CT-guided planni®cation (either
2D or 3D), seems to be performed in nearly all centers. Only
six centers are not using CT at all. This re¯ects the general
quality of the treatment planning. Kim et al. have shown that
the most common site of an inadequate margin is located at
the position of the rectal block resulting in a geographical
miss in 39±50% of the patients in stage Ib±IVa [20]. This is
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followed by the posterior margin in 25±32% of the cases. If
the anterior surface of the sacrum is included, a dramatic
drop to almost no geographical misses at the posterior
border of the lateral ®elds is observed, suggesting that a
four-®eld box technique with customized blocking should
not be used unless a dedicated CT is available [20]. In the
present survey, six centers do not use CT-guided planni®ca-
tion, and four of them are treating the pelvic volume with a
four-®eld box technique. The posterior limit and the use of
individualized blocks in the lateral ®eld have not been
inquired in the present survey, and therefore we cannot
really assess if there is an increased risk of geographical
miss. A second question relates to the volumes to be treated
with external radiation therapy, especially the irradiation of
para-aortic nodes. The RTOG trial demonstrates a 10-year
survival bene®t (44 vs. 55%) in bulky Ib (cancer diameter of
more than 4cm) and IIa cervical carcinoma if para-aortic
lymph nodes are included in the target volume, although
there is no difference in disease-free survival nor in the
control of local disease between pelvic irradiation and
pelvic plus para-aortic irradiation [33]. The reported 10-
year survival difference can be explained by a lower inci-
dence of distant failures, eventually with a better salvage in
complete responders who later failed locally, or a difference
in the death-rate due to treatment-related complications (see
late effects). One should be aware that 37% of those patients
did not have their para-aortic nodes evaluated surgically or
radiologically. The EORTC trial performed on more
advanced cervix cancer (comparing pelvic plus para-aortic
vs. pelvic volume in early clinical stages with positive LAG
or histologically proven pelvic nodes, and LACC, i.e. IIb
and III), does not show any bene®t in survival, local control
or overall distant metastases [14]. There was a clear increase
in the incidence of severe digestive complications in
patients receiving para-aortic irradiation (9 vs. 4.8%)
[14,41]. However, considering the reduced incidence of
para-aortic and distant metastases in patients without recur-
ring tumor at pelvic sites, if treated with extended ®elds, the
authors proposed to treat para-aortic nodes where there is a
high probability of local control [14]. In the present survey,
about 90% of the centers are treating this large volume if
they have arguments for positive para-aortic and/or pelvic
lymph nodes.
A third important parameter relates to the quality of the
brachytherapy. Brachytherapy is an essential component of
treatment in LACC, although there is no consensus on the
optimal dose-rate. A majority of centers are using LDR. A
randomized trial comparing HDR vs. LDR showed similar
5-year survival rates, but a signi®cant difference in favor of
LDR as far as toxicity is concerned (10% moderate to severe
complications in HDR compared to 4% in LDR) [39]. The
question on dose-rate is not de®nitely settled, with some
authors con®rming the importance of dose-rate, although
at a different level, i.e. comparing two low dose-rate levels
[23], and others rejecting the conclusions of the Osaka trial
stating that there is no increase in late toxicity [35].
4.2.3. Chemotherapy
The addition of chemotherapy to radiotherapy has
become standard in the treatment of LACC [34]. Morris et
al. demonstrated in a randomized trial the bene®cial effects
of adding 5-¯uoro-uracil and cisplatinum to radiotherapy in
LACC, resulting in a signi®cant improvement in survival
(from 73 vs. 58%) [26]. The Gynecologic Oncology Group
compared, in a randomized fashion, cisplatin vs. cisplatin
plus hydroxyurea, and 5-¯uorouracil vs. hydroxyurea alone
[32]. Cisplatin containing regimens improve the survival
and progression-free survival in LACC [32].
One might expect major changes in treatment prescrip-
tions following these randomized trials. The frequency of
adjunctive chemotherapy already changed from 6% in 1984
to 24.8% in 1990. In the patterns of care study, 12% of the
patients were treated with concurrent chemotherapy at the
cost of a greater morbidity [25,27]. In view of an unproven
bene®t at that time, it is interesting to note the frequency of
use of chemotherapy and especially neoadjuvant
chemotherapy. One could wonder why some patients with
LACC are still submitted to neoadjuvant chemotherapy, as a
suf®cient amount of data issued from randomized trials
show a deleterious effect on survival [24,30,36,37]. A
substantial reduction in survival from 39 to 23% at 5
years has been shown by Souhami et al., comparing radio-
therapy to neadjuvant chemotherapy followed by radiother-
apy in patients with FIGO stage IIIb [37]. The issue of
chemotherapy is not de®nitely settled and a lot more empha-
sis will be put on concomitant chemo±radiotherapy, espe-
cially after these two positive randomized trials. The
advantages are spatial cooperation and additive or supra-
additive effects on the primary tumor. For spatial coopera-
tion, one should realize that distant metastases as the ®rst
site of failure are rare (5±15%), and that distant metastases
are not related to the stage. Regarding the effect on the
locoregional control, most of the drugs are used because
of their capacity to sensitize cancer cells to ionizing irradia-
tion. Cisplatin is one of the most frequent agents reported to
be used, together with radiotherapy, in the present survey.
Indeed, clinical experience favors cisplatin as the drug of
choice in various human tumors. However, some experi-
mental data in vitro, especially on human cervix cancer
cell lines, show that cisplatin leads to additive toxicity and
not radiosensitization [4].
4.3. New approaches
Possible factors affecting the outcome in the treatment of
LACC are intrinsic radio-resistance, tumor proliferation and
hypoxia. Most of the centers of the RCG are willing to
participate in trials addressing these issues. The highest
rating is obtained for a trial combining chemotherapy as a
concomitant sensitizer to radiotherapy, which obviously
would require running phase I/II trials if drugs like taxol
or gemcitabine have to be used, because the data indicate an
increase in gastrointestinal toxicity.
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The importance of reducing the overall treatment-time is
also considered an important issue in the treatment of
LACC. This re¯ects evidence issued from retrospective
studies addressing the importance of the `time package
deal' in LACC [6,11,12,21,28,29,40]. As stated by Eifel
`a comparison between policies that emphasize early intra-
cavitary treatment and short 5±6-week overall treatment-
times with those that emphasize an initial course of pelvic
treatment to achieve greater tumor regression before
brachytherapy would be of considerable interest' [8].
Last but not least, hypoxia is certainly an issue in cervix
cancer, as shown by different authors performing in vivo
measurements and seeking a correlation between low
tumor pO2 and outcome [16,17]. The hypoxia in cervix
tumors provides a physiological selective pressure for the
expansion of HPV-infected epithelial variants that have lost
their apoptotic potential, which is deemed to be a supple-
mentary reason for radiation resistance [13,19]. The Radia-
tion Therapy Oncology Group tested misonidazole as a
hypoxic cell-sensitizer in a randomized trial; no improve-
ment in survival was observed [2]. The Gynecology Oncol-
ogy Group compared hydroxyurea vs. misonidazole with no
improvement in survival [38].The Medical Research Coun-
cil Working Party on advanced carcinoma of the cervix ran
another randomized trial with Ro 03-8799 (pimonidazole)
as a hypoxic cell-sensitizer. They observed no bene®t by
adding pimonidazole to radiotherapy, and a truly adverse
effect of the drug was a possible cause of failure in this
trial [7]. A new approach is the use of bio-reductive
drugs, such as tirapazamine (SR-4233), which in contrast
to misonidazole and pimonidazole, offers a selective way of
killing those resistant hypoxic cells.
The presence of HPV opens new directions for radiation
biology research, as it is currently known that HPV onco-
proteins E6 and E7 inhibit both p53 and Rb proteins, both
playing an essential role in the cell cycle machinery, and
hence, in¯uencing the cell-cycle response to stress [18].
Mechanisms of inhibition of E6 and E7 expression could
reinstore p53 functionality and modify radiation response.
5. Conclusions
Several questions are unresolved in cervix cancer. These
uncertainties are re¯ected in the answers provided by the
members of the RCG on questions related to staging, treat-
ment options and techniques, and on innovative approaches
to be tested within trials. However, a clear shift in patterns
of care does occur in cervix cancer treatment. There seems
to be a decrease in the number of earlier stages secondary to
screening policy, but on the other hand, there is a suf®cient
number of IIIa and IIIb disease, leaving some space for trials
within Europe. Our survey re¯ects the interest within the
RCG to launch and participate in a large prospective multi-
center trial in Europe. However, we need an educational
program to improve our `standards' of care, and to adhere
to the principles of evidence-based medicine. A comprehen-
sive quality-control program is mandatory, especially due to
the complexity of the combination of external irradiation
and brachytherapy. As a matter of fact, this program is a
prerequisite to launching any kind of trial in LACC.
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